@article{CDT21427,
author = {Andreas Eicken and Peter Ewert},
title = {Percutaneous tricuspid valve implantation in failing bioprosthesis},
journal = {Cardiovascular Diagnosis and Therapy},
volume = {8},
number = {6},
year = {2018},
keywords = {},
abstract = {Severe tricuspid valve (TV) dysfunction in patients with congenital heart disease (CHD) is usually treated by open heart surgery in relatively young patients. If a valve plasty is not possible, a biological valve is implanted with a limited durability. Due to valve degeneration repeated valve exchanges are necessary in these patients. To expand the lifetime of a bioprosthesis in tricuspid position percutaneous TV implantation (PTVI) was introduced recently. PTVI is a promising new catheter interventional technology. The current review summarizes the indication for PTVI, describes the procedure itself and gives an outlook on medium to long-term results of this catheter intervention. PTVI in patients with severe TV dysfunction is less invasive, safe and effective, if performed by an experienced operator, and may help to reduce the total number of open-heart surgeries during a patient’s life time. However, further studies with larger patient numbers and longer follow-up are needed.},
issn = {2223-3660}, url = {https://cdt.amegroups.org/article/view/21427}
}